The question of who pays for providing and upgrading systems for FMD is a key one for all involved in the medicines supply chain.
The Directive itself makes it clear that the costs of establishing the European Hub (EMVS) and each National Medicines Verification System (NMVS) is to be borne by “manufacturers” (i.e. companies holding marketing authorisations for branded, generic or parallel traded products). This is likely to be in the form of licensing payments related to the number of products being marketed and the volumes of data being uploaded.
However, pharmacy owners will have to pay the costs of connecting to a national system themselves. This includes any equipment needed, such as new scanners.
Each of the four national community pharmacy negotiators (PSNC, CPS, CPW and CPNI) is working to ensure that contractors’ FMD-related costs are recognised in future NHS funding settlements.